Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPAL Cohort C: Niraparib vs Platinum-Taxane Neoadjuvant in HRD Ovarian Cancer
2023-505097-16-00Phase 2Completed
- Sponsor
- TESARO, Inc.
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of niraparib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by TESARO, Inc. Primary endpoint: Pre-IDS unconfirmed objective response rate (ORR). Started Feb 2024; status: completed.
02
Drugs
niraparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2023-505097-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505097-16-00.